

# United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

DATE MAILED: 10/13/2004

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/672,020	09/29/2000	Thomas J. Gardella	0609.4820002/SRL/TBB	2982
26111 75	90 10/13/2004		EXAMINER	
	SSLER, GOLDSTEIN	MURPHY, JOSEPH F		
1100 NEW YORK AVENUE, N.W. WASHINGTON, DC 20005			ART UNIT	PAPER NUMBER
			1646	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	09/672,020	GARDELLA ET AL.			
Office Action Summary	Examiner	Art Unit			
	Joseph F Murphy	1646			
The MAILING DATE of this communic		th the correspondence address			
Period for Reply					
A SHORTENED STATUTORY PERIOD FO THE MAILING DATE OF THIS COMMUNIC  - Extensions of time may be available under the provisions of after SIX (6) MONTHS from the mailing date of this commur  - If the period for reply specified above is less than thirty (30)  - If NO period for reply is specified above, the maximum statu  - Failure to reply within the set or extended period for reply wi Any reply received by the Office later than three months afte earned patent term adjustment. See 37 CFR 1.704(b).	ATION.  37 CFR 1.136(a). In no event, however, may a rication. days, a reply within the statutory minimum of thirt tory period will apply and will expire SIX (6) MON III. by statute, cause the application to become AB	eply be timely filed by (30) days will be considered timely. ITHS from the mailing date of this communication. SANDONED (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed	on <u>06 August 2004</u> .				
	o)⊠ This action is non-final.				
• **	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.				
Disposition of Claims					
4) Claim(s) 1,3-8 and 10-44 is/are pending 4a) Of the above claim(s) 4-7 and 13-4 5) Claim(s) is/are allowed. 6) Claim(s) 8, 42, 44 is/are rejected. 7) Claim(s) 1,10-12 and 43 is/are objected. 8) Claim(s) are subject to restriction. Application Papers 9) The specification is objected to by the 10) The drawing(s) filed on is/are:	41 is/are withdrawn from considerated to. on and/or election requirement.  Examiner. a) □ accepted or b) □ objected to	by the Examiner.			
Applicant may not request that any object Replacement drawing sheet(s) including to 11) The oath or declaration is objected to	he correction is required if the drawing	(s) is objected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for a) All b) Some * c) None of:  1. Certified copies of the priority d  2. Certified copies of the priority d  3. Copies of the certified copies of application from the Internation  * See the attached detailed Office action	ocuments have been received. ocuments have been received in A f the priority documents have been al Bureau (PCT Rule 17.2(a)).	Application No  received in this National Stage			
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PT 3) Information Disclosure Statement(s) (PTO-1449 or Paper No(s)/Mail Date	O-948) Paper No(	Summary (PTO-413) s)/Mail Date Informal Patent Application (PTO-152)			

Application/Control Number: 09/672,020

Art Unit: 1646

#### **DETAILED ACTION**

#### Formal Matters

Claims 1, 3-8, 10-44 are pending. Claims 1, 8, 10-12, 42-44 are under consideration. Claims 4-7, 13-41 stand withdrawn from consideration pursuant to 37 CFR 1.142(b).

### Response to Amendment

The rejection of claims 1, 8, 10-12, 42 under 35 U.S.C. 112, first paragraph, has been obviated by Applicant's amendment and are thus withdrawn.

The rejection of claims 1, 10-12, 42 under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

New and remaining issues are set forth below.

#### Claim Objections

Claims 1, 8, 10-12, 42-44 are objected to because of the following informalities: The use of the subscript number identifiers of the X amino acids are objected to because they make the claims unclear. For instance, claims 42, 44 refer to fragments containing amino acids 1-9 etc., while SEQ ID NO: 1 is listed as containing  $X_{01}$  etc., this is confusing since it is not clear whether the 1 is the same as the 01. This claim could be clarified by using letters as the subscript identifiers for the X amino acids, e.g.  $X_a$ . Appropriate correction is required.

Application/Control Number: 09/672,020

Art Unit: 1646

## Claim Rejections - 35 USC § 112 second paragraph

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 8, 42 and 44 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 8 recites the limitation "The biologically active polypeptide of claim 1". There is insufficient antecedent basis for this limitation in the claim, because the base claim has been amendment to remove the language "biological activity".

Claims 8 stands rejected as being vague and indefinite in the recitation of the term "biologically active". The term "biologically active" is not defined by the claim, and give no definition of what this activity is.

Claims 42 and 44 are vague and indefinite because of the recitation of the term "thereof" in subsections (b) and (c). It is not clear to which protein the subsections are referring to.

Presumably the subsections are referring to SEQ ID NO: 1, this rejection could be obviated by clarifying the protein to which these subsections refer.

Claims 42 and 44 are vague and indefinite in the recitation of "N- or C- derivatives". It is not clear what this term refers to. There is no guidance provided as to what specific sequences the term "N- or C- derivatives" refers to, and there is no definition provided in the Specification, therefore, the metes and bounds of these claims are unclear.

Application/Control Number: 09/672,020

Art Unit: 1646

#### Conclusion

Claims 1, 10-12, 43 are objected to.

Claims 8, 42, 44 are rejected.

#### Advisory Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Joseph Murphy whose telephone number is (571) 272-0877. The examiner can normally be reached Monday through Friday from 7:30 am to 5:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda Brumback can be reached on (571) 272-0961.

The fax number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Joseph F. Murphy, Ph. D. Patent Examiner Art Unit 1646 October 7, 2004

JOSEPH MURPHY PATENT EXAMINER